Work on the nasal vaccine.
Will corona patients increase in cold?
Hyderabad Co-vaccine testing of India’s first indigenous coronavirus vaccine on human organs has reached Phase III. Bharat Biotech, which is engaged in the manufacture of Corona vaccine, on Monday raised questions about its reach to all the people of the country. Bharat Biotech has called the vaccination of 130 crore people a challenge to get rid of corona. Bharat Biotech International Limited (BBIL) Chairman and Managing Director Krishna Ella said that the company’s Bio-Safety Level-3 (BSL-3) facility is currently of limited capacity, but to reach a 100 crore dose by next year have hope
260 crore syringes will be needed
Ella addressed the Dexon Dialogue organized by the Indian School of Business (ISB) in collaboration with the Ministry of External Affairs, stating that “We have partnered with ICMR for covicin and we are entering the Phase III trials of Corona vaccine manufacture , But I’m not happy, because it’s an injectable two-dose vaccine. If we want to vaccine the two-dose vaccine to a population of 130 million, we’ll need 260 million syringes and needles. “
Work on the nasal vaccine –
Ella said that we are working on another vaccine. This is a drop-in vaccine vaccine. I think by next year we will make this vaccine available to one billion population. He said that the challenge is to get 130 crore population vaccinated.
Will the corona grow in the cold?
Professor M. Vidyasagar of the Indian Institute of Technology (IITT), Hyderabad, who is also the chairman of the ‘Kovid-19 Indian National Supermodel Committee’, said that the challenge is whether the cold weather in North India particularly aggravates this epidemic. Is and can we guess it. He said that India had more success in controlling the epidemic than other countries like America, Britain and France, whose death rate is seven to eight times higher than India.